Ontuxizumab
Ontuxizumab[1] is a humanized rabbit monoclonal antibody[2] designed for the treatment of cancer. It binds to endosialin (TEM1 or CD248).[3]
Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Chimeric/humanized hybrid (mouse/human) |
Target | TEM1 |
Clinical data | |
ATC code |
|
Identifiers | |
CAS Number | |
ChemSpider |
|
UNII | |
Chemical and physical data | |
Formula | C6532H10050N1726O2054S44 |
Molar mass | 147.0 kg/mol g·mol−1 |
Phase I trials are complete and the drug was granted orphan drug status by the FDA for sarcoma. It is currently in phase II trials for melanoma, colorectal cancer, sarcoma, and lymphoma.[4]
This drug was developed by Morphotek and Ludwig Institute for Cancer Research.[5]
References
- World Health Organization (2013). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 109" (PDF). WHO Drug Information. 27 (2).
- "Endosialin binding molecules". Philip M. Sass, Brad Kline, Nicholas Nicolaides, Luigi Grasso, Stephen Harley, Morphotek Inc. 2010-04-08. Cite journal requires
|journal=
(help)CS1 maint: others (link) - Kiyohara, E; Donovan, N; Takeshima, L; Huang, S; Wilmott, J. S.; Scolyer, R. A.; Jones, P; Somers, E. B.; O'Shannessy, D. J.; Hoon, D. S. (2015). "Endosialin Expression in Metastatic Melanoma Tumor Microenvironment Vasculature: Potential Therapeutic Implications". Cancer Microenvironment. 8 (2): 111–8. doi:10.1007/s12307-015-0168-8. PMC 4542822. PMID 26085332.
- http://adisinsight.springer.com/drugs/800032178
- http://adisinsight.springer.com/drugs/800032178
This article is issued from
Wikipedia.
The text is licensed under Creative
Commons - Attribution - Sharealike.
Additional terms may apply for the media files.